a weight loss drug trial
Skin laxity related to the use of GLP-1 receptor agonists is now a primary concern in aesthetic medicine, according to Macrene Alexiades, MD, PhD, FAAD, director and founder of the Dermatology & Laser Center of New York and a Healio Dermatology Peer Perspective Board Member
FDA and European Medicines Agency (EMA) have concluded that there is no direct evidence for the association of the use with GLP-1RAs with pancreatitis or pancreatic cancer
Neurology (2010) 75(22):19827
Keep the pen in place for at least 10 seconds, starting from the moment you push it against your skin
That study showed that, for people with overweight or obesity taking a GLP-1, the risk of the incident (new occurrence) of suicidal ideation is almost 75% lower, and the risk of it happening again (recurrence) is over 50% lower